URL Slug: /blog/glp-1-cardiovascular-benefits-select-trial Target Keyword: semaglutide heart health benefits SEO Title: Semaglutide Heart Health Benefits: What the SELECT Trial Found
Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
A patient came to see me about a year ago carrying a printout from a news article about semaglutide and heart disease. He was 58 years old, had a history of a myocardial infarction four years prior, and his BMI was 31. He had been told by two previous physicians that GLP-1 therapy was for diabetics and for people with severe obesity. He sat across from me and asked if that was still true.
I told him it was not. The SELECT trial changed how I think about semaglutide heart health benefits in ways that go beyond expanding a patient population. It forced a reckoning with a question that had been sitting in the background of cardiovascular medicine for years: whether the cardiovascular benefit we were seeing in GLP-1 trials was a consequence of lowering blood sugar, or whether it reflected something more fundamental about how these drugs interact with the cardiovascular system.
What the SELECT Trial Was and Why It Matters
The SELECT trial was published in the New England Journal of Medicine in November 2023. It enrolled 17,604 adults across 41 countries. The participants were 45 years of age or older, had a BMI of 27 or above, had established cardiovascular disease, and had no history of diabetes. (PubMed) This last criterion is what separated SELECT from everything that came before it.
Every patient in this trial was already receiving aggressive cardiovascular risk reduction — statins, antihypertensives, antiplatelet agents. Semaglutide was tested as an additional intervention against that standard-of-care background. Participants were randomized to receive either once-weekly subcutaneous semaglutide at 2.4 mg or placebo and followed for a mean of 33 months.
The Primary Endpoint: What MACE Means and Why It Is the Right Measure
The primary endpoint of SELECT was MACE: major adverse cardiovascular events. MACE is the gold standard composite endpoint in cardiovascular outcomes research because it captures the three events that define the prognostic reality of heart disease: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. These are not surrogate markers or intermediate biochanges. They are the outcomes that kill and disable patients with established cardiovascular disease.
The SELECT trial found a 20 percent relative risk reduction in MACE in the semaglutide group compared to placebo. The hazard ratio was 0.80, with a 95 percent confidence interval of 0.72 to 0.90, and a p-value below 0.001. Among patients already on widespread statin therapy and aggressive cardiovascular risk management, semaglutide still reduced the primary endpoint by 20 percent.
If a patient has a 10-year MACE risk of 20 percent, a 20 percent relative reduction brings that risk to approximately 16 percent. Four fewer events per 100 patients over that time horizon. In a population as large and high-risk as the one enrolled in SELECT, that is an enormous number of prevented deaths, strokes, and heart attacks.
Why This Is Different From Every Prior GLP-1 Trial
Before SELECT, the cardiovascular evidence for GLP-1 receptor agonists came from trials in diabetic populations. The LEADER trial with liraglutide showed a 13 percent reduction in MACE in patients with type 2 diabetes. (PubMed) The SUSTAIN-6 trial with semaglutide showed a 26 percent reduction in MACE in patients with type 2 diabetes. (PubMed) Both were compelling results. But both left open a critical interpretive question: was the cardiovascular protection a consequence of improved glycemic control, or was it something the drug was doing independently of its glucose-lowering effects?
SELECT removed that question from the table. There was no diabetes in this population. No glycemic mechanism could explain the outcome. Something else was driving the benefit.
The Mechanisms Behind a Non-Glycemic Cardiovascular Benefit
GLP-1 receptors are expressed in cardiac tissue, not only in the pancreas and gut. At the cardiac level, GLP-1 receptor activation reduces local inflammation, improves cardiac energetics by shifting myocardial substrate utilization toward more oxygen-efficient pathways, and has been shown in preclinical models to reduce ischemia-reperfusion injury. These are direct effects on the heart muscle, operating independently of weight loss or glucose changes.
Weight loss itself carries cardiovascular benefits that are separate from metabolic improvements. Reducing body weight decreases cardiac preload by reducing circulating volume and venous return to the heart, and decreases cardiac afterload by reducing the systemic vascular resistance that an enlarged body mass imposes. Over months and years, these hemodynamic improvements reduce the mechanical burden on a heart that has already experienced ischemic damage.
There is also an anti-inflammatory mechanism. Visceral adiposity is metabolically active in ways that promote systemic inflammation, and inflammation is a direct driver of atherosclerotic plaque development and destabilization. As visceral fat decreases with semaglutide treatment, circulating inflammatory cytokines fall, and the inflammatory microenvironment within existing atherosclerotic plaques may change in ways that reduce the likelihood of acute rupture and thrombosis.
Who This Applies To and How I Think About Eligibility
SELECT enrolled patients who were overweight or obese, had established cardiovascular disease, and were not diabetic. That describes a very large number of people who have had a heart attack, a stent placement, a stroke, or a diagnosis of peripheral arterial disease or coronary atherosclerosis, who carry excess weight, and who have been told that semaglutide was not indicated for them.
The reality after SELECT is that these patients are exactly who this therapy was tested in and found to benefit. For a patient with established cardiovascular disease and a BMI of 27 or above, semaglutide now belongs in the risk reduction conversation alongside statins and antihypertensives. The framing of GLP-1 as a diabetes drug does not survive contact with a 17,604-person randomized controlled trial showing a 20 percent reduction in cardiovascular death, myocardial infarction, and stroke in a non-diabetic population.
My eligibility thinking has shifted considerably. I now approach patients with prior cardiovascular events and excess weight as candidates for a conversation about semaglutide on the same terms I would approach a conversation about adding a second antihypertensive or a PCSK9 inhibitor.
A Note on Access and the Current Regulatory Environment
For patients who are appropriate candidates for semaglutide-based cardiovascular risk reduction, the access question matters. Branded semaglutide (Wegovy at 2.4 mg, the dose studied in SELECT) can exceed $1,000 per month without insurance coverage, and coverage for weight management indications remains inconsistent across plans.
The regulatory landscape for compounded semaglutide has changed significantly since 2024. The FDA’s shortage-based pathway that allowed broad compounding of semaglutide ended when the shortage was declared resolved in February 2025. What remains available through the 503A framework is patient-specific compounding when a licensed prescriber documents a clinical need the commercial product cannot address — a specific dose strength, for example.
Patients evaluating their options should understand both what the branded product offers and what the current compounding framework permits. For a full explanation of the 503A framework and what responsible compounding involves, see What I Tell Every Patient Who Asks Whether Compounded Semaglutide Is Real Medication. For a direct comparison of compounded semaglutide and branded Ozempic/Wegovy, see Is Compounded Semaglutide the Same as Ozempic?.
⚠️ [LEGAL/COMPLIANCE FLAG FOR JP/COUNSEL]: This section references the post-shortage 503A framework for access. Please confirm that this accurately describes Precision Telemed’s current semaglutide offering and that the program is positioned appropriately given the SELECT trial’s specific use of the 2.4 mg Wegovy dose — a dose that may require specific documentation if accessed through compounding.
Precision Telemed’s Semaglutide Program
At Precision Telemed, compounded semaglutide is available at $149 per month, fulfilled through 503A compounding pharmacies, and managed entirely through async telehealth. Patients in all 50 states can access a clinical evaluation without an in-person visit.
For patients who have a cardiovascular history and have been turned away from GLP-1 therapy because a previous provider was not current with the SELECT data, I would encourage a direct conversation with a licensed provider about their specific history and labs. The indication picture changed in November 2023. The old answer is no longer the right answer for a lot of people.
FAQ
What was the SELECT trial? The SELECT trial was a randomized, placebo-controlled clinical trial published in the New England Journal of Medicine in 2023. It enrolled 17,604 non-diabetic adults with established cardiovascular disease and a BMI of 27 or above, testing once-weekly semaglutide 2.4 mg against placebo over a mean of 33 months, with all participants on background standard cardiovascular care.
What did the SELECT trial find? Semaglutide reduced the risk of MACE — the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke — by 20 percent compared to placebo. The hazard ratio was 0.80 (95% CI 0.72–0.90, p less than 0.001), in a population with no history of diabetes.
Does semaglutide only benefit people with diabetes? No. The SELECT trial was specifically designed to test non-diabetic patients. The cardiovascular benefit was observed in the complete absence of a glycemic mechanism, which indicates the benefit comes from the drug’s direct cardiovascular effects, anti-inflammatory properties, and hemodynamic improvements from weight loss.
What does MACE mean and why does it matter? MACE stands for major adverse cardiovascular events: the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke. It is the standard primary endpoint in cardiovascular outcomes trials because it captures the most serious and life-altering events that heart disease produces. A 20 percent relative reduction in MACE reflects prevention of actual deaths and disabling events.
What are the non-glycemic mechanisms behind semaglutide’s cardiovascular benefit? Three primary mechanisms appear to operate. First, GLP-1 receptors in cardiac tissue mediate direct anti-inflammatory and cardioprotective effects. Second, sustained weight loss reduces cardiac preload and afterload, lowering the mechanical burden on the heart. Third, reductions in visceral adiposity lower systemic inflammatory cytokine levels, which may stabilize atherosclerotic plaques.
Who should consider semaglutide for cardiovascular risk reduction? Based on the SELECT trial, patients with established cardiovascular disease and a BMI of 27 or above represent the population in which cardiovascular benefit has been directly demonstrated. Whether semaglutide is appropriate for a specific individual depends on their full medical history, current medications, and a clinical evaluation by a licensed provider.
Is compounded semaglutide as effective as branded semaglutide? It is impossible to make this distinction since compounded semaglutide has never been studied. Compounded semaglutide uses the same active pharmaceutical ingredient as branded formulations when prepared by a licensed 503A compounding pharmacy under appropriate quality controls. Patients should discuss the current regulatory basis for any compounded semaglutide prescription with their provider, particularly given the changes in the compounding landscape since early 2025.
Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
References
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PubMed
- Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844. PubMed
- Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. 2016;375(4):311-322. PubMed
To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult your healthcare provider.